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Abstract
Background: Public health research provides evidence for practice across fields including health care, health
promotion and health surveillance. Levels of public health research vary markedly across European Union (EU)
countries, and are lowest in the EU’s new member states (in Central and Eastern Europe and the Mediterranean).
However, these countries now receive most of the EU’s Structural Funds, some of which are allocated to research.
Methods: STEPS, an EU-funded study, sought to assess support for public health research at national and
European levels. To identify support through the Structural funds, STEPS drew information from country
respondents and internet searches for all twelve EU new member states.
Results: The EU allocates annually around €7 billion through the Structural Funds for member states’ own use on
research. These funds can cover infrastructure, academic employment, and direct research grants. The programmes
emphasise links to business. Support for health research includes major projects in biosciences, but direct support
for public health research was found in only three countries - Cyprus, Latvia and Lithuania.
Conclusions: Public health research is not prioritised in the EU’s Structural Funds programme in comparison with
biomedicine. For the research dimension of the new European programme for Structural Funds 2014-2002,
ministries of health should propose public health research to strengthen the evidence-base for European public
health policy and practice.
Introduction
Public health, undertaken at organisational and system
level through disease prevention and improving the effi-
ciency and effectiveness of health care, contributes
importantly to population health and social wellbeing.
Evidence is needed to develop public health policies and
practice.
Work in a previous EU study, SPHERE, described
public health research from a European perspective [1].
A strong geographical gradient in publication rates,
highest in the Scandinavian countries and UK and low-
est in the southern and Eastern Europe, was found for
all public health publications and within six sub-disci-
plinary themes [2]. STEPS (Strengthening Public Health
Research in Europe) was developed and funded through
the EU’s Science in Society programme to investigate
the gradient further. The objective of STEPS was to
assess the public health research systems in Europe and
the contribution of civil society organisations to health
research in the EU ‘new member states’.
STEPS held workshops at national level in the 12 EU
‘new member states’ - the ten countries in Central East-
ern Europe (Bulgaria, Czech Republic, Estonia, Hungary,
Latvia, Lithuania, Poland Romania, Slovakia and Slove-
nia) and two in the Mediterranean (Cyprus and Malta)
joining the EU in 2004 and 2007. The workshops, led by
civil society organisations and involving researchers and
ministries of health, were focused on national public
health research structures and perspectives [3]. STEPS
also developed country health research profiles for all 27
EU countries, describing funding of health research and
support for universities and national research institutes
[4]. The workshops and country profiles showed that all
countries have strategies for research overall, but fewer
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have strategies specifically for health research, nor for
public health research [5]. National governments pro-
vide most funding, with non-profit foundations; there is
no contribution by the commercial sector.
The European Union funds research directly through
the European Commission’s Directorate for Research
and Innovation. In the EU Seventh Framework Pro-
gramme, 2007-2013, health is a leading research theme,
with €1 bn allocated per annum. Within this, one of
three funding strands is for public health research,
which has supported more than 70 collaborative projects
in Europe over the first three years [6].
However, the STEPS country workshops and profiles
revealed a second stream of funding from the EU for
research - from its Structural Funds. These funds form
around a quarter of the EU’s budget, and are directed
towards support for poorer countries and regions within
the Union. The use of the Structural Funds directly for
health services has been reported [7] and is the subject
of a collaborative study EUREGIO III [8]. The potential
for use of the Structural Funds for public health
research is investigated here.
Methods
Public health research was defined broadly as research at
health system and organisational levels, including health
care, health promotion and health surveillance, differing
from biomedical research at laboratory and clinical levels.
The European Commission’s web sites Erawatch [9] and
Pro-Inno Policy TrendChart [10] provides baseline coun-
try information (reporting up to 2009 when accessed in
2011) across all areas of research, and with a primary
emphasis towards research for technology and business.
Information was recorded for the twelve countries join-
ing the European Union in 2004 and 2007.
Students from EU new member states attending the
UCL School of Eastern European and Slavonic Studies
identified national web page resources about the Struc-
tural Funds in their own languages, and provided an
initial scoping of the data available. The country part-
ners in STEPS were also tasked to determine the infor-
mation on the use of the Structural Funds for research,
and to provide overview reports. Structures for commis-
sioning health research by country were also available
through STEPS [4].
While the Structural Funds were developed within a
common template of funding from the European Com-
mission, the 12 new member states each record the
information in different ways, in different categories and
with different levels of detail. Therefore, further searches
were made of national web pages using Google Trans-
late. The findings of these searches were summarised
and brought together for comparison.
Results
The European Union’s budget, comprising just over 1%
of total GNP of the member states, is allocated in two
major tranches - 43% for ‘natural resources’ (mainly the
common agricultural policy), and 37% for ‘cohesion pol-
icy’. (The budget for research, education and training is
around 7% of the total, and for the Health Directorate
only 0.07%.) In the period 2007-2013, the EU has allo-
cated most of the Structural Funds to the 12 EU ‘new’
member states, which have levels of GDP less than 75%
of the EU average [11]
There are three funds for Cohesion Policy [12]. The
European Regional Development Funds (ERDF) are
“helping regions to anticipate and promote economic
change through innovation and the promotion of the
knowledge society”. The European Social Funds (ESF)
are “strengthening competitiveness and employment
by...investment in human resources, the development of
qualifications and competences, [and] the dissemination
of information and communication technologies”. The
third, much small fund, Cohesion Funds (CF) contri-
butes in the same ways as ERDF and ESF, and provides
enhanced support for the smaller countries.
Allocations within the Structural Funds are negotiated
by each country with the European Commission’s Direc-
torate for Regions. The Commission sets the total sum
(mainly based on population), reporting structure
(Operational Programmes) and broad priorities (which
included R&D), while member states determine the bal-
ance of these resource against their own priorities.
Funds are allocated in the European Regional Develop-
ment Funds for ‘physical’ infrastructures, and in the
European Social Fund for ‘human’ resources. Allocations
in the Operational Programmes that support research
included university and science buildings, studentships
and other training, and formal research calls.
How much funding? how is it used?
The Structural Funds are spent on programmes devised
and implemented by the member states, not centrally by
the European Commission. However, country pro-
grammes are agreed with the Commission, and follow
EU policies. Over the full period 2007-2013, around €86
billion, almost 25% of the total, is described as directed
to research and innovation [13]. Of this, €50 billion is
for “R&D and innovation in the narrow sense” - includ-
ing €10 billion infrastructure, €9 billion for investment
in firms, €6 billion each for R&TD research centres,
assistance to SMEs, and improvement of networks, €5
billion in developing human potential, and €3 billion for
SMEs environmentally-friendly products and processes.
A request for information directly to the European
Commission received the following reply: “Concerning
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the rate of implementation of this €86 billion, the latest
available figures (Annual Implementation Reports 2009,
provided by the Member States in July 2010) show that
about € 30 billion have been allocated to specific pro-
jects (out of which €16 billion for R&D&I in a narrow
sense). The remaining part can be committed before the
end of the 2013. Moreover, about 3% of the €30 billion
(and 5% of the €16 billion) have been allocated to speci-
fic projects in the area of Human Health.” [correspon-
dence to author]
Little information is published by the Commission on
the actual use of the Structural Funds in the current
programme, except gross expenditures. On the web
page for Cohesion Policy [14], there is a drop-down
menu for Projects. The 12 EU countries have together
56 projects listed, across engineering, technology and
life sciences. Five projects listed are health-related,
including organisation of cross-border care (Czech
Republic), an ambulatory care centre (Slovakia), breast
screening (Poland), support for pharmaceutical informa-
tion (Hungary) and a molecular genomics centre
(Malta). However, the first two are service developments
rather than research, and the last three are laboratory
technology rather than public health research.
Use for health research in new member states
STEPS used national web pages to identify the use of
Structural Funds for health research in the EU new
member states. The majority of these 12 countries had
general R&D levels well below the EU average at the
beginning of the period, at 0.6% of GNP or less,
although two countries, Czech Republic and Slovenia, at
1.6% were closer to the EU’s average level of 1.9%, with
Hungary, Estonia, and Lithuania at between 1% and
0.8%. The overall allocation of the Structural Funds is
strongly influenced by the population size of the country
- Poland receives a quarter of the total, and small coun-
tries gain much less. However, the information available
from the larger countries is less satisfactory than in
some smaller countries, and the other countries provide
important examples of alternative approaches.
Some countries, eg Estonia, Latvia, Lithuania and Slo-
vakia, stand out in using the Structural Funds actively
for research, and a few have developed competitive
research calls from their funds. Some countries have put
funding primarily into ‘centres’, eg Slovenia. And in
some countries, for example Malta and Slovakia, there is
evident use of the ESF human resources funds to pro-
mote research capacities, with masters, doctorate and
post-doctorate programmes. Bulgaria, by contrast, has
apparently no direct investment for research, although
innovation could be supported in “R&D institutions and
organizations, municipalities, private or public bodies
including NGOs”.
The funds are administered through Operational Pro-
grammes in very different ways [Table 1]. A minority of
countries use their existing research management insti-
tutions - for example, Cyprus placed its Structural
Funds for research in the Research Promotion Founda-
tion. In contrast, Malta placed €20 m for a molecular
genetics centre within an agency working under the
Ministry of Finance. Often it was not clear which orga-
nization is managing the funding. While in the main the
allocations were not identified to academic fields, in a
few countries there were developments of biomedical
centres with capital costs - for example, Czech Republic
proposes a molecular biology centre outside Prague of
€100 m. Only in one country, Lithuania, was there evi-
dence of research for public health research, under the
title ‘administrative capacity and efficient public
administration’
Discussion
Understanding of the use of the Structural Funds for
health research is limited by the data sources. The Eur-
opean Commission’s internet sites provide only high-
level information on country research systems [9,10].
The European Commission-funded study of the use of
the Structural Funds for health [8] does not cover health
research. STEPS Country respondents have described
national public health research structures [4], and some
more detailed information can be found on country web
pages in national languages. This contrasts with infor-
mation about research available through the European
Commission Directorate for Research, which has well-
advertised calls and reports at the end of thematic pro-
grammes (although the underlying databases remain dif-
ficult to interrogate [15]).
The budget available for research through the Struc-
tural Funds appears, at least on paper, to be equal in
size to the total available for the EU’s Research Pro-
gramme. But the two programmes are managed sepa-
rately by two European Commission directorates. The
Framework Research Programme has a system of
National Focal Points, often members of the national
research funding agency, but they do not disseminate
information about research through the Structural
Funds; and ministries of science and education did not
show how the Structural Funds contribute to their bud-
gets. This may be because ministries of finance have to
report co-funding for the Structural Funds to the Eur-
opean Commission: in general, member states ‘badge’
the funding as national, so it is impossible to determine
how much the Structural Funds themselves have
assisted. Our study found that research call programmes
were being managed in some countries by the Structural
Funds agency of the Ministry of Finance, rather than by
the national research agency, creating a ‘parallel’ system.
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Table 1 Research and the Structural Funds in the 12 EU new member states
Comment Research and the Structural Funds
Bulgaria
Very limited activity for health research
Bulgaria has a low level of research funding, 0.50% of GDP (2008).
The seven Operational Programmes do not directly identify R&D. The fourth, Competitiveness, Axis 1.2 (€75
m) includes ‘pro-innovative infrastructure’, ‘pro-innovative services and ‘innovation networks’ - with
beneficiaries “R&D institutions and organizations, municipalities, private or public bodies including NGOs”.
Also in April 2009, Operational Programme “Regional Development” allocated €17 million for support/
upgrading of universities.
CYPRUS
Actively using SF for research programmes, including (small) public health research
Cyprus has low expenditure on R&D at 0.49% (2009). Cyprus has three private universities and no medical
school (although one is developing in North Cyprus). Of €83 million R&D funds, 45% (€38 m) was directly
from government funds, €19 m from the universities’ budgets, €10 m from abroad (including €8 m from EU)
and €16 m from the private sector (€5 m pharmaceuticals).
Cyprus has €640 million Structural Funds. RTDI has been implemented through the Cyprus Research
Promotion Foundation. There have been two National Research Frameworks (DESMI) - in 2008 €48 million,
and for 2009-2011 €40. These were allocated: €33.4 m for natural sciences, €16.6 m social sciences, €14.6 m
engineering and technology, €10.2 m agricultural sciences, €5.1 m humanities, €3.2 m health and biological
sciences (including public health research). Other State support for biomedical research includes €5 million
annually for Cyprus Institute of Neurology and Genetics (University of Nicosia).
Czech Republic
Strong R&D programme, including biomedicine but not public health research
Czech Republic has medium level investment in R&D at 1.6% of GDP, with public sector investment 38%
and private sector 62%.
The Operational Programme Research for Development and Innovation has €2 billion, which includes €685
million (33%) for equipment and infrastructure, €685 million (33%) for R & D institutes focused on applied
research, strengthening their cooperation with industry (including hospitals) according to the needs of the
region, €414 million (20%) for universities’ infrastructure of laboratories and IT, and €72 million (3%)
monitoring of projects and programmes, studies and analysis, programme publicity, and training and
consultancy services. A further operational programme for universities and Academies, funded through the
Ministry of Education, Youth and Sports, provides €154 million institutional support.
The programme Call 1.2 (2009) for Regional R&D centres had 18 successful applications, predominantly in
technical engineering. In Nov/Dec 2010, biomedicine has been favoured with a €100 million molecular
genetics centre at Vestec near Prague for Charles University (the project coordinator is the former President
of the Academy of Science) and a €12 million Regional Centre of Applied Molecular Oncology at Brno.
Estonia
Strong SF investment in R&D infrastructures and research programmes. No public
health research.
R&D in Estonia has grown from 0.6% of GDP in 2000 to 1.4% in 2009. Spend is 39% natural sciences, 19%
engineering, humanities, 15% medical and health sciences, 12% humanities, 9% social sciences, 5%
agricultural sciences. Over 2007-2013, Estonia receives 3.4 billion - European Regional Development Fund
support of €1.86 billion, Cohesion Fund €1.15 billion euros, and European Social Fund €390 million.
ERDF supports €306 million for infrastructure and development of institutions, small-scale research
equipment, R&D in biotechnology and other targeted programmes, and international collaboration.
Operational Programme for Human Resource Development, operated by the Estonian Ministry of Education
and Research receives €102 million euros (plus €14 m state co-funding). Programmes include Mobilitas,
supporting postdoctoral research (€20 million euros), implemented by the Estonian Science Foundation (July
2011 there had been five rounds of calls for ‘top researcher grants’), and state’s Archimedes Foundation
funding internationalization of doctoral studies (€32 million).
Hungary
Strong use of SF for R&D. Support to industry and higher education institutes. No focus
for public health research.
There is a low rate of research investment in Hungary at 1% of GNP.
The Structural Funds (€22.4 billion) are allocated through 15 Operational Programmes of the National
Development Plan. RTDI activities are mainly supported under the Economic Development Operational
Programme (EDOP). Priority 1 “R&D and innovation for competitiveness” has €822 m over 7 years from ERDF
for three fields: the promotion of market-oriented R&D; innovation clusters and technology parks; and R&D
activities by enterprises.
The Social Infrastructures Operational Programme supports research and educational infrastructure at HEIs,
and the Social Renewal Operational Programme for collaborative RTDI, including basic research. Together






















Table 1 Research and the Structural Funds in the 12 EU new member states (Continued)
Latvia
SF used actively for infrastructures and R&D calls. Small public health research support.
Latvia has a low rate of research, 0.61% of GDP (2008).
In the ESF operational programme Priority “Higher Education and Science” includes “Attraction of Human
Resources to Science” (€47 m) and “Support to Doctor’s and Master’s study programmes” (€58 m). But many
of the scheduled activities were cancelled with the financial crisis.
In the ERDF 2.1 Priority “Science and Innovation” has €451 m ERDF support. This includes “Science, Research
and Development” for investigator-initiated proposals (€50 m). In a call in 2010, from 177 proposals 114
were financed. A second activity “Development of the scientific and research infrastructure” covers
infrastructural development in 10 National research centres and the development of scientific computing
network with total ERDF support €175 m. Among these 10 centres is the national research centre in public
health and clinical medicine.
In the 3rd operational programme “Infrastructure and Services” (ERDF/CF), €168 m is given to development
of infrastructure for higher education, including large equipment. Activity “Development of Science and
Technology park of Riga”, originally intended to support biomedical research, has been put on hold because
of absence of suitable land for development, as a consequence of privatisations.
Lithuania
Strong use of SF for research - industry, human capacities and programmes.
Strong list of public health research support.
Lithuania has a relatively low level of research at 0.82% of GDP in 2007.
The annual Structural Funds for Lithuania 2007-2013 are €1 bn, around 15% of the total national budget.
Planning with stakeholders was developed from 2005. Support for research and innovation is well-
developed under all three priority areas.
Operational Programme 1-3: ‘Enhancement of researchers’ capacities’, coordinated by the Ministry of
Education and Science, includes development of scientists and researchers, thematic networks and R&D
training (€140 m).
Operational programme 2.1: ‘R&D for competitiveness and growth’ has €602 m, includes infrastructure
projects, ‘high level research centres’, business parks and integrated studies
Operational Programme 3.2: Priority 1.4 Strengthening of Administrative Capacity and Increase of Efficient
Public Administration (€178 m) includes Priority 1-4.3 (€37 m), which integrated science, study and business
centres (valleys), joint research programmes, strengthening the Lithuanian Scientific Council, and the
development of monitoring of science and studies.
Research supported by this last measure include the analysis of public health care carried out by
municipalities, studies to identify the scope of public health services, the development of a monitoring
system, creation of models for providing public health services, training and professional development of
public health care specialists, creation of a demand planning system as well as improvement and
development of public health impact assessment.
Malta
Moderate use of SF for public sector research infrastructures and human resources, but
not public health research.
In 2007, Malta spent 0.6% of GDP on research and development. Business contributed the largest proportion
of funds with €21 m (65%) (largely multinational firms undertaking in-house R&D), followed by higher
education €10 m (31%), with public research organisations just €1 m (3.3%).
Malta’s Structural and Cohesion Funds for 2007-2013 total €855 m. Just under 10% is allocated to
‘Knowledge & Innovation’, mainly for infrastructures (eg the IT faculty at the university, strengthening
university laboratories in engineering, biotechnology and chemistry, €49 m). Malta Enterprises, an agency
working under the Ministry of Finance, receives €20 m for a Life Sciences Centre (molecular genetics). An
Educational Pathways Scholarship Scheme for Post-Graduate studies (MSc, PhD) is established with €10 m,






















Table 1 Research and the Structural Funds in the 12 EU new member states (Continued)
Poland
Very large overall SF available, smaller proportion for R&D, focus on technologies, no
public health research
The research expenditure in Poland is low (0.61% GDP in 2008), mainly non-competitive public funding
through a large number of higher education institutes and academies.
The Structural Funds for Poland 2007-2013 at €67.3 billion are the largest for any member state, allocated in
four main programmes. The smallest, the Operational Programme Innovative Economy, with €8.85 billion
from ERDF, has two research-related programmes: ‘Research and development of new technologies’ (€1.1
billion) covering informatics, technologies and biotechnologies (includes ‘new medical products and
techniques’).
The Operational Programme Infrastructure and Environment (€27.9 billion) includes Priority 12 ‘Health
security and improving the efficiency of the health system’ (€350 m from ERDF), although this is not related
to research. Priority 13, ‘Infrastructure of higher education’ (€500 m from ERDF) covers infrastructures, access
and improving the quality of education through IT.
In the Human Capital Programme (€9.7 billion) is Priority 4.2, ‘Developing R&D staff qualifications and
increasing awareness of science importance to economic growth’ (€61 m.).
Regional Operational Programmes (€16.6 billion) have been created for each of the 16 provinces. Some
Regional Innovation Strategies include innovation networks and R&D.
Romania
Substantial SF funding, moderate use for research infrastructures and human resources,
and competitive programme calls include ‘health’ but not public health.
Romania has a low level of R&D investment (0.58% GDP in 2008). There is growing use of competition in
public funding of research, and of the structural funds to support research, but substantial public budget
cuts in 2009.
Romania gains €19.6 billion from EU Structural and Cohesion Funds. Funded by ERDF, the Operational
Programme “Increase of economic competitiveness” includes Axis 2: Research, Technological Development
and Innovation for competitiveness (€536 m), which is managed through the National Authority for
Scientific Research and addresses five of the nine priorities of the national RDI strategy, including (first)
‘Health’.
The Operational Programme ‘Human Resources Development’ funded by ESF, has Axis 1 with €797 m for
higher education, and includes University education for the knowledge society’ and ‘Doctoral and
postdoctoral programmes in support of research’.
Slovakia
Strong SF use for research university infrastructures, human resources and programme
calls, including clinical research.
Slovakia’s proportion of R&D was low at 0.49% by 2007. However, R&D is the main thrust for the 2007-2013
Structural Funds, with €1.2 billion allocated for the Research and Development, €883 m for Convergence,
and €326 m for Regional Competitiveness and Employment.
Over €500 m was put out to 13 calls in 2009, which included grants for research of around €1 m each
(including clinical research studies), for ‘centres of excellence’ of around €4 m (including environment and
health, stroke and perinatology), and grants for SMEs, including several for biomedical technology.
The Operational Programme Education, with a total of €617 m, includes Measure 2.1, support for tertiary
education (€28 m in 2009 call), as well as Measure 2 2 ‘Support for life-long learning in the Health sector’,
with sub-objectives of building human resources for the health system and promoting continuing education
(no calls yet under this heading).
The Operational Programme, Competitiveness and Economic Growth includes a thematic programme for
universities’ buildings and infrastructures, with a budget of €1.2 bn
Slovenia
Moderate SF use for R&D public infrastructures, SMEs and technology. No public health
research.
Slovenia has a medium level of investment in R&D at 1.6% of GDP in 2008.
The total EU Structural Funds are €4.2 billion, divided into five programmes. The first of these, Strengthening
Regional Development Potential has €1.7 billion (40%), with five operational programmes, of which the first
‘Competitiveness and Research Excellence’ receives €402 m (24%).
In a competitive call for 2009-2013, eight Centres of Excellence for infrastructures programmes and
operation were chosen (out of 60 applications), each receiving €10 m: all were in technology, with one in























While public health research is not prioritised inde-
pendently within the Structural Funds for research infra-
structures, human capacities or research programmes, in
Cyprus, Latvia and Lithuania public health appeared to
be supported within broader health research. In other
countries it is possible that some generic support comes
through increased ministry of education funding to uni-
versities: but this contrasts with the direct mention in
many of the Operation Programmes of funding for engi-
neering and technical sciences, and indeed biotechnol-
ogy for health sciences. Public health research could
compete if calls are developed appropriately, and deci-
sion-making boards have the appropriate representation
for decision-making. Lithuania appears to have taken
this forward with a programme for public health
research, although the fields now covered could be
widened further.
An underlying problem of priorities is the European
Union’s priority of support for business [11]. Research
and innovation are beneficial for economic ‘growth’; yet
manufacturing is only a small part of the total of wes-
tern European economies, and more than 60% is now
‘services’. Innovation through human resources and
technologies can be social as well as physical, and out-
side the factory skills, quality and achievements are
determined as much by social as by technological fac-
tors. This is particularly the case for public health,
where national policy, professional practice and scienti-
fic knowledge interact, and implementation requires
internalisation within cultures beyond commercial mar-
kets. There is a need to re-emphasise the importance of
not-for-profit research in science [16,17].
Public health research could benefit substantially from
the Structural Funds. New institutes, research units and
courses could develop within the expanding higher edu-
cation sector. The research activities do not require
expensive laboratories and technical equipment (apart
from computing). And public health is a field with a
positive gender balance. The challenge is for ministries
of health - which would benefit importantly from invest-
ment in public health research - to recognise the oppor-
tunity. For the Structural Funds in 2007-2013, ministries
of health put forward cases for support for both health
systems and buildings - and were generally successful,
with specific Operational Programmes in most countries
[7]. But, despite the high importance of health in
research agendas - in European and most national pro-
grammes - few ministries of health have internal struc-
tures that take a direct interest in research, and have
not influenced the priorities of the Structural Funds
(through their national ministries of finance). This situa-
tion is exacerbated by the historic links of the life
sciences with ministries of science rather than ministries
of health, and the traditional preference of science
academies for basic and ‘physical’ sciences rather than
applied and ‘social’ sciences.
The content of the EU programmes for 2014-2020 will
be decided in 2012 and 2013 through decisions between
the Council of Ministers (member states), Parliament
(political processes) and European Commission (assess-
ments and implementation). The Structural Funds
remain a major part of the EU budget, after the Com-
mon Agricultural Policy. In the present funding period,
the Structural Funds spend as much in support of
research as the EU’s official budget for research, yet
without any of the controls, data and policies that are
needed to improve value. Moreover, the European Com-
mission’s Directorate for Regions which allocates and
monitors the Structural Funds does not give priority
attention to research, and neither the Commission’s
Directorate for Research nor the Directorate for Health
have information on how member states are using
Structural Funds for research.
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